Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

Igawa,Satoshi; Yanagisawa,Nobuyuki; Niwa,Hideyuki; Ishihara,Mikiko; Hiyoshi,Yasuhiro; Otani,Sakiko; Katono,Ken; Sasaki,Jiichiro; Satoh,Yukitoshi; Masuda,Noriyuki

doi:10.3892/ol.2015.3812

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

Authors:
- Satoshi Igawa
- Nobuyuki Yanagisawa
- Hideyuki Niwa
- Mikiko Ishihara
- Yasuhiro Hiyoshi
- Sakiko Otani
- Ken Katono
- Jiichiro Sasaki
- Yukitoshi Satoh
- Noriyuki Masuda
View Affiliations

Affiliations: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan, Department of Pathology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan, Department of Thoracic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan
Published online on: October 19, 2015 https://doi.org/10.3892/ol.2015.3812
Pages: 3519-3522

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymic large cell neuroendocrine carcinomas (LCNECs) are rare, and the optimal regimen for second and subsequent lines of chemotherapy for the treatment of LCNECs remains unknown. In the present case study, a 59‑year‑old male with post‑operative recurrent thymic LCNEC was treated with nab‑paclitaxel and carboplatin every 4 weeks as third‑line chemotherapy, and a partial response was achieved following 4 cycles of this regimen. The patient developed grade 4 neutropenia and grade 3 leukopenia, but none of the other toxicities, including peripheral neuropathy, were severe. Therefore, the patient was able to tolerate this salvage chemotherapy. To the best of our knowledge, the present study is the first case demonstrating clinically meaningful antitumor activity by combination chemotherapy with carboplatin and nab‑paclitaxel, resulting in a positive response in a patient with thymic LCNEC.

View Figures

View References

1	Shimosato Y, Kameya T, Nagai K and Suemasu K: Squamous cell carcinoma of the thymus: An analysis of eight cases. Am J Surg Pathol. 1:109–121. 1977. View Article : Google Scholar : PubMed/NCBI
2	Suster S and Rosai J: Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer. 67:1025–1032. 1991. View Article : Google Scholar : PubMed/NCBI
3	Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S and Fujii Y: Thymic carcinoma 30 cases at a single institution. J Thorac Oncol. 3:265–269. 2008. View Article : Google Scholar : PubMed/NCBI
4	Marx A, Shimosato Y, Kuo TT, et al: Thymic neuroendocrine tumours. In: World Health Organization Classification of Tumours. Pathology and genetics of tumors of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: (Lyon). IARC Press. 188–195. 2004.
5	Wick MR and Rosai J: Neuroendocrine neoplasms of the mediastinum. Semin Diagn Pathol. 8:35–51. 1991.PubMed/NCBI
6	Ogawa F, Iyoda A, Amano H, Nezu K, Jiang SX, Okayasu I and Satoh Y: Thymic large cell neuroendocrine carcinoma: Report of a resected case - a case report. J Cardiothorac Surg. 5:1152010. View Article : Google Scholar : PubMed/NCBI
7	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
8	Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
9	Koizumi W, Morita S and Sakata Y: A randomized phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). Jpn J Clin Oncol. 45:303–306. 2015. View Article : Google Scholar : PubMed/NCBI
10	Chirgwin J and Chua SL: Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review. Breast. 20:394–406. 2011. View Article : Google Scholar : PubMed/NCBI
11	Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 12:1317–1324. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH and Loehrer PJ Sr: Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 29:2060–2065. 2011. View Article : Google Scholar : PubMed/NCBI
13	Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, et al: Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer. 67:194–197. 2010. View Article : Google Scholar : PubMed/NCBI
14	Takeda K, Hirai F, Yamanaka T, Taguchi K, Daga H, Shimizu J, Kogure Y, Kimura T, Tanaka K, Iwamoto Y, et al: A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L. ASCO Annual Meeting Abstracts. J Clin Oncol (Suppl). 31:75292013.
15	Kawashima Y, Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Sakakibara T, Maemondo M, Asahina H, et al: Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803. ASCO Annual Meeting Abstracts. J Clin Oncol (Suppl). 31:75302013.
16	Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H, Kubota K, Kakinuma R, Nagai K, Suga M and Nishiwaki Y: Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer. 98:926–931. 2003. View Article : Google Scholar : PubMed/NCBI
17	Agatsuma T, Koizumi T, Kanda S, Ito M, Urushihata K, Yamamoto H, Hanaoka M and Kubo K: Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol. 6:2130–2134. 2011. View Article : Google Scholar : PubMed/NCBI
18	Jackman DM and Johnson BE: Small-cell lung cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
19	Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, et al: Thoracic Oncology Research Group Study 0301: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
20	Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, et al: A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer. 84:67–72. 2014. View Article : Google Scholar : PubMed/NCBI
21	Groen HJ, Fokkema E, Biesma B, Kwa B, van Putten JW, Postmus PE and Smit EF: Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin and etoposide: A non-cross-resistant schedule. J Clin Oncol. 17:927–932. 1999.PubMed/NCBI
22	Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y and Fujisawa T: Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 82:1802–1807. 2006. View Article : Google Scholar : PubMed/NCBI
23	Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Asamura H, et al: Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer. 49:217–223. 2005. View Article : Google Scholar : PubMed/NCBI